Altamira Therapeutics Ltd. · OTC:CYTOF

Altamira Therapeutics — Auris Medical Holding — Q2 2014 Earnings Presentation

17 slides from Altamira Therapeutics's earnings presentation, Sep 15, 2014

  1. Slide 1: Second Quarter 2014 Earnings and Business Update

    Second Quarter 2014 Earnings and Business Update September 15, 2014

  2. Slide 2: Forward Looking Statements / Safe Harbor

    Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral com

  3. Slide 3: Business Update

    Business Update

  4. Slide 4: AM-101 Phase Program Update

    AM-101 Phase 3 Program Update [] AM-101 Phase 3 clinical program in acute inner ear tinnitus remains on track [] Ramp-up of TACTT trial sites progressing -- Approximately 100 sites initiated by the end of August 2014 (target 140) -- Poland and Czech Republic getting started [] As expected, Stratum B

  5. Slide 5: Tinnitus Loudness Responder Definition

    Tinnitus Loudness Responder Definition [] Primary efficacy endpoint in Phase 3 = improvement of subjective loudness from baseline to the last follow-up visit at Day 84 on a 0-10 numerical rating scale [] What represents a clinically meaningful reduction in tinnitus loudness / how is a responder defi

  6. Slide 6: Responder Data Presented at ITS 2014

    Responder Data Presented at ITS 2014 [] Results presented at XI. International Tinnitus Seminar in Berlin, Germany, May 21-24, 2014 [] Anchor-based approach suggesting 2 point reduction as clinically meaningful -- Pattern of TLQ response compared to patient global impression of change (PGIC) in tinn

  7. Slide 7: Cumulative Distribution Function for TLQ

    Cumulative Distribution Function for [] TLQ [] For all points 0, the curve for AM-101 0.81 mg/mL is shifted to the right of the others [] At 2 points change in TLQ, AM-101 0.81 mg/mL clearly separates from placebo and AM- 101 0.27 mg/mL, providing further support for responder definition

  8. Slide 8: Auris Medical at the AAO Annual Meeting

    Auris Medical at the AAO Annual Meeting [] Annual Meeting of the American Association for Otolaryngology -- Head and Neck Surgery [] Orlando FL, September 21-24 [] World's largest gathering of ENTs [] Auris Medical hosting satellite symposium September 23

  9. Slide 9: AM-101 Primary Market Research

    AM-101 Primary Market Research [] 53 US ENT doctors surveyed(1) -- 41 general ENTs -- 12 otologists [] Seeing an average of 43.5 tinnitus patients in an average month [] 37.7% of their tinnitus patients seek treatment during the acute stage (up to 3 months from onset) [] Consistent with survey by Ha

  10. Slide 10: AM-111 Program Update

    AM-111 Program Update [] Preparations for the AM-111 late stage clinical program in ASHNL progressing [] Pivotal HEALOS Phase 3 trial planned in ISSNHL -- 240 patients with severe to profound hearing loss -- AM-111 0.4 or 0.8 mg/mL or placebo -- Up to 72 hours from onset -- Europe and Asia [] Protoc

  11. Slide 11: AM-111 Primary Market Research

    AM-111 Primary Market Research [] 53 US ENT doctors surveyed(1) -- 41 general ENTs -- 12 otologists [] Seeing an average of 11.2 patients with ISSNHL and 6.3 patients with AAT in an average month [] 39.9% show up for treatment within first 3 days [] 43.3% of their ASNHL patients have severe to profo

  12. Slide 12: Intellectual Property Update

    Intellectual Property Update [] Additional patent applications filed in US relating to the use of inhibitors of the c- Jun N-Terminal Kinase (JNK) such as AM-111 -- for the treatment of tinnitus -- for the treatment of Meni[]re's Disease [] Continuation to earlier US application filed relating to th

  13. Slide 13: Financial Update

    Financial Update 12

  14. Slide 14: First Half 2014 Financial Highlights

    First Half 2014 Financial Highlights [] Cash and cash equivalents as of June 30, 2014, were CHF 12.1 m compared to CHF 18.5 m at March 31, 2014 and CHF 23.9 m at December 31, 2013 [] Research and development expenses increased from CHF 6.4 m in the six months ended June 30, 2013 to CHF 8.4 m in the

  15. Slide 15: Financial Overview Financial Position

    Financial Overview Financial Position [] Cash at end of H1 2014 = $13.7 m [] $60.7 m raised in IPO in early August 2014 ($56.4 m after underwriting discount) -- 10,113,235 common shares sold at $6 per share (incl. 713,235 shares under over-allotment option) -- Trading on the NASDAQ Global Market sta

  16. Slide 16: Questions and Answers

    Questions and Answers

  17. Slide 17: Take care of your ears!

    Take care of your ears! 16

Auris Medical Holding — Q2 2014 Earnings Presentation on 6ix